Fibrocell Science (FCSC) is Initiated by ROTH Capital to Buy, Price Target at $14

Fibrocell Science (FCSC) is Initiated by ROTH Capital to Buy according to the research report released to the investors. The brokerage firm has set the Price Target of the shares at $14. The shares recommendation by the Brokerage Firm was released on Dec-22-2015.

Fibrocell Science Inc (NASDAQ:FCSC) : On Thursday heightened volatility was witnessed in Fibrocell Science Inc (NASDAQ:FCSC) which led to swings in the share price. The shares opened for trading at $5.02 and hit $5.24 on the upside , eventually ending the session at $5.15, with a gain of 3.62% or 0.18 points. The heightened volatility saw the trading volume jump to 72,826 shares. The 52-week high of the share price is $7.6 and the company has a market cap of $226 million. The 52-week low of the share price is at $2.31 .

During the last several months other analysts have commented on the company rating. In a research note released to the investors, Wedbush downgrades its rating on Fibrocell Science Inc (NASDAQ:FCSC).The analysts at the brokerage house have a current rating of Neutral on the shares. Earlier, the shares were rated a Outperform by the brokerage firm. In a recent information released to the investors, Wedbush lowers the new price target from $7 per share to $6 per share. The rating by the firm was issued on September 28, 2015.

Research firm Zacks has rated Fibrocell Science Inc (NASDAQ:FCSC) and has ranked it at 3, indicating that for the short term the shares are a hold. 2 Wall Street analysts have given the company an average rating of 2. The shares has received a hold rating based on the suggestion from 1 analysts in latest recommendations. Strong buy was given by 1 Wall Street Analysts.

Fibrocell Science Inc (NASDAQ:FCSC): 2 Analyst have given the stock of Fibrocell Science Inc (NASDAQ:FCSC) a near short term price target of $11. The standard deviation reading, which is a measure by which the stock price is expected to swing away from the mean estimate, is at $7.07. The higher price target estimate is at $16 while the lower price estimates are fixed at $6.

Shares of Fibrocell Science, Inc. appreciated by 4.25% during the last five trading days but lost 4.28% on a 4-week basis. Fibrocell Science, Inc. has dropped 22.21% during the last 3-month period . Year-to-Date the stock performance stands at 98.84%.

Fibrocell Science, Inc. is an autologous cell therapy company focused on developing treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. The Company’s lead orphan drug program is in late-stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Working in collaboration with Intrexon Corporation, a synthetic biology company, Fibrocell is genetically modifying autologous fibroblast cells to express target proteins that are inactive or missing from patients with rare genetic skin and connective tissue disorders. It is also pursuing medical applications for azficel-T, which is the Company’s proprietary autologous fibroblast technology for restrictive burn scarring and vocal cord scarring. Both indications are in Phase II clinical trials.